A high number of human islets can be isolated by using modern purified tissue dissociation enzymes; however, this requires the use of >20 Wunsch units (WU)/g of pancreas for digestion. Attempts to reduce this dose have resulted in pancreas underdigestion and poor islet recovery but improved islet function. In this study, we achieved a high number of functional islets using a low dose of recombinant collagenase enzyme mixture (RCEM-1200 WU rC2 and 10 million collagen-degrading activity [CDA] U of rC1 containing about 209 mg of collagenase to digest a 100-g pancreas). The collagenase dose used in these isolations is about 42% of the natural collagenase enzyme mixture (NCEM) dose commonly used to digest a 100-g pancreas.
| 479
LOGANATHAN eT AL.
transplantation. Pancreas digestion with an optimal formulation and dose of collagenase-protease enzyme mixture is crucial for obtaining high-quality islets, as it relies heavily on the potency and consistency of these enzymes during the islet isolation procedure. 4 To ensure a safe, pure, and potent islet product, regulatory requirements require that the islet product be consistently manufactured by using a standardized and validated process. [5] [6] [7] Although significant improvements have been made in the purification of Clostridium histolyticum collagenase, variations in collagenase and protease activity between different lots of the same product are common. 8, 9 This variation is likely caused by degradation of class I or class II collagenase during bacterial fermentation or the subsequent purification process. Proteolysis of intact collagenase leads to variability, affecting its ability to degrade native collagen. 10, 11 Purified natural collagenase is also commonly contaminated with clostripain, a sulfhydryl neutral protease (NP) with trypsin-like activity 12 ,13 that appears to increase endogenous protease activity via activation of pancreatic proenzymes. 14, 15 Only a small portion of clostripain is active under oxidizing conditions, which further contributes to the variability in protease activity between lots of the same product.
The dose and composition of the enzymes used in the pancreas digestion process are critical factors that affect the number and quality of islets released from the human pancreas. In most islet laboratories, a collagenase dose of >20 WU/g pancreas (1 full vial of collagenase bottle) is commonly used. 4, 16 Recently, it was reported that a vast amount of collagenase fails to be absorbed by the human pancreas during the digestion process, suggesting that an excess of collagenase is commonly used 17 Cross et al. 18 demonstrated that collagenase can penetrate human islets after intraductal administration. Excess collagenase may potentially harm islets during the isolation process.
Conversely, islet functionality may be improved with the use of lower doses (<20 WU/g) of natural collagenase. However, lower doses result in poor islet recovery, due to higher percentages of undigested tissue.
Manufacturing purified recombinant collagenases may overcome problems commonly encountered with purified natural collagenase.
Recombinant class I (rC1) and class II (rC2) collagenase are expressed from single genes in the Escherichia coli strain containing low protease activity. This minimizes proteolysis of collagenase enzymes, leading to the generation of intact rC1 and rC2 enzymes. Clostripain contamination is eliminated, improving the control of protease activity during the islet isolation procedure.
In our recent study, 19 we successfully manufactured purified rC1 and rC2 and assessed 4 different collagenase formulations to recover islets from human pancreases (n = 12, 3 per group). Varying amounts of rC1 and rC2 collagenase activity, supplemented with a fixed amount of P. polymyxa NP activity (BP-Protease [VitaCyte LLC, Indianapolis, IN], a dispase-equivalent NP), were tested using a statistically designed experiment in a split-pancreas model. We observed that the low-dose collagenase-protease enzyme mixture (RCEM, 100 000 CDA U, 12 WU/g tissue, in combination with 23 400 U of BP-Protease/g tissue) digested the pancreas and recovered islets as effectively as the 3 other enzyme mixtures that contained 1.38-to 1.79-fold higher mass of recombinant collagenase enzymes per g tissue. These RCEMs contained about 42% to 75% of the mass of purified natural collagenase commonly used for digesting a 100-g pancreas.
In this study we used a low RCEM dose (12 WU/g) to successfully isolate islets, with good functionality, from whole human pancreata.
These results, compared with islet isolation performed using natural collagenase enzyme mixture (60:40 C1:C2 mixture containing about 530 mg collagenase to digest a 100-g pancreas) (NCEM) with equivalent (12 WU/g) or standard (20 WU/g) amounts, demonstrated better islet recovery, tissue digestion efficiency, insulin secretion, and transplantation outcomes. This is the first report indicating that islet functionality can be improved with low-dose enzyme. Overall, the quality and functionality assessments suggest that this RCEM dose has potential to be used for human islet isolations to improve clinical outcomes.
| MATERIALS AND METHODS

| Donor pancreases
Human cadaveric donor pancreases (n = 20) were obtained through the Kentucky Organ Donor Affiliates (Louisville, KY) from brain-dead donors after informed consent had been obtained as part of a multiorgan procurement. Pancreases were transported in cold UW solution.
| Islet isolation enzymes (rC1 + rC2 + BP-Protease)
Purified recombinant or natural collagenase enzymes were prepared as reported earlier. 19 The only animal component used in the prepa- 
| Human islet isolation
Islet isolations were performed as previously reported. 20 On arrival, the pancreas was trimmed, cannulated, and distended with digestive enzymes. The rC1 and rC2 collagenases (rC1 100 000 CDA U/g, rC2
12 WU/g) were mixed with BP-Protease enzymes (23 400 NP U/g pancreas) at the time of islet isolation to generate the RCEM (n = 7).
Enzymes were diluted in 350 mL of HBSS for each pancreas. After ductal perfusion of the enzymes, the pancreas was digested in a Ricordi chamber (Biorep Technologies, Miami, FL) using a modification of Ricordi's semiautomated method. 21 The digested tissue was 
| Islet morphology, histology, and viability assessment
Islets were stained with dithizone, and islet morphology was assessed and scored. Islet histology assessment was performed according to previously published methods. 22 Islet viability was assessed by using the fluorescein diacetate-propidium iodide method. 
| Islet surface assessment by scanning electron microscopy
Scanning electron microscopic (SEM) images of isolated islets with either standard NCEM dose or low RCEM dose were obtained, to compare surface morphology. Freshly isolated pure islets were fixed in 2% glutaraldehyde and dehydrated by using successive increases in ethyl alcohol percentages (70-100%). Hexamethlydisilazane was then applied over these dehydrated islets for chemical drying. Islets were mounted on SEM stubs, sputter coated with gold (Au), and processed for SEM imaging. Isolated islets from NCEM served as the control. 
| Basal insulin release before and after enzyme exposure
Islet basal insulin release into culture medium (48 hours) was evaluated after islets were isolated with a low or standard dose of RCEM or NCEM. 25 In subsequent studies, islets were cultured for an additional 48 hours under normal conditions. These cultured islets were further exposed to low and standard RCEM and NCEM doses for 30 minutes.
After multiple washing with serum-containing medium, the cells were cultured again for 48 hours before assessment of basal insulin release. These results were compared with those obtained with the untreated control. Insulin was measured by using an ELISA kit (Mercodia, Winston-Salem, NC).
| Glucose-stimulated insulin release by static and dynamic methods
After overnight culture, islet insulin secretion was assessed by in vitro static and dynamic glucose challenge using low ( 
| Enzyme-exposed islet transplantation
The effect of enzyme exposure on islet function was monitored in diabetic nude mice by assessing the in vivo islet insulin secretion. Total endotoxin burden in the system, endotoxin unit total
BAEE, Nα-benzoyl-l-arginineethylester hydrochloride; CDA, collagendegrading activity.
a rC1 or rC2 expressed by separate E. coli clones and purified separately.
the University of Louisville (n = 15, 3 in each condition). Mice were considered diabetic (streptozotocin induced) once their blood glucose levels were 350 mg/dL or higher for 2 consecutive days. Post transplantation, the mice blood glucose levels and body weight were measured daily for the first week, then every 3 days until the completion of study. Return of normoglycemia in cured mice was identified by 2 consecutive drops of blood glucose levels to 200 mg/dL or less. At 30 days post transplantation, a left nephrectomy was performed in the normoglycemic mice to confirm a return to hyperglycemia, validating causality.
| Assessing transplanted islet graft function by intraperitoneal glucose tolerance test
Enzyme-exposed islets were challenged with high glucose by use of an intraperitoneal glucose tolerance test (IPGTT0).
After overnight fasting, the animals were injected intraperitoneally with glucose dissolved in 0.9% sodium chloride solution (2 g glucose/ kg body weight). Blood samples were obtained before (0 minute) and 15, 30, 60, and 90 minutes after glucose injection and analyzed for blood glucose measurement. 
| Statistical analysis
All results were expressed as the mean ± SD. Islet yield comparisons and insulin secretion were analyzed by using the nonparametric Kruskal-Wallis test followed by the post-hoc Dunn method for multiple comparisons and the Friedman test followed by the Dunn correction, respectively. Statistical significance for the analysis was set at P < .05.
| RESULTS
| Islet isolation and functional outcome
Islet isolation outcomes using the low-dose RCEM are summarized in Table 2 . Table 3A compares these preparations with islets isolated using a standard dose of RCEM or a low or standard dose of NCEM. The low dose of NCEM gave significantly lower islet yields (2582 ± 925 IEQ/g pancreas) and a higher percentage of undigested pancreas (37.8 ± 3%) compared with those isolations using low-dose RCEM (5535 ± 830 IEQ/g pancreas and 16.7 ± 5%, P < .05). There were no significant differences in islet yield or percent digested tissue between low-dose RCEM or islets isolated with the standard-dose NCEM or RCEM.
To validate effectiveness of low-dose RCEM on islet isolation, basal insulin secretion and glucose-stimulated insulin release (GSIR) response
were measured and compared with values from other enzyme formulations. The functional outcomes of islets isolated using different enzyme mixture doses are summarized in Table 3A and 3B. Islets isolated with low-dose RCEM gave significantly higher basal insulin release after 48 hours of culture compared with islets isolated with the standard dose of NCEM (2391 ± 1342 vs 1778 ± 978 μU/mL; P < .05). There was no significant difference in basal insulin release when comparing T A B L E 2 Human islet isolation outcomes using a low-dose RCEM (100 000 CDA U, 12 WU/g tissue) supplemented with 23 400 U/g tissue of BP-Protease islets isolated with low-or standard-dose RCEM or low-dose NCEM.
All islet preparations gave similar GSIR stimulation indices when assessed by static or dynamic insulin secretory assays (Table 3A) .
To further confirm the functional ability of low-dose RCEM over NCEM, isolated islets from 1 preparation were stabilized for 48 hours in culture and then subjected to various enzyme doses to measure islet function. This allowed us to evaluate enzyme effect on islet function by minimizing discrepancies arising due to donor-todonor variability. Isolated islets after stabilization were exposed to either low-or standard-dose RCEM and NCEM and cultured for an additional 48 hours. Basal insulin release measurements from these culture islets were similar with the exception of a significant difference between low-dose RCEM and standard-dose NCEM (Table 3B , P < .05), suggesting that using low-dose RCEM results in better functioning islets.
| Morphology, histology and SEM assessment of isolated islets
Islets isolated with RCEM (12 WU/g) or NCEM (20 WU/g) demonstrated no difference in morphology after hematoxylin and eosin staining (not shown). However, RCEM isolated islets under SEM revealed a smooth surface with few single cells exposed ( Figure 1A ). In contrast, more visible surface damage was observed ( Figure 1B ) after islet isolation with NCEM. Overall, our results so far suggest that islets isolated using RCEM retain better functionality and morphology over islets isolated using NCEM.
| In vivo assessment of islet function
To determine the in vivo effects of islets isolated using RCEM, we 
| DISCUSSION
The key findings in this report are that low-dose RCEM gave significantly higher human islet yields than comparable low-dose NCEM and significantly better in vivo islet function after transplantation into nude mice. In addition, SEM images indicate less surface damage to T A B L E 3 Human islet isolation and functional outcome using different doses of enzyme blends RCEM, recombinant collagenase enzyme mixture; NCEM, natural collagenase enzyme mixture; GSIR, glucose-stimulated insulin release. * ,# Values generated for each condition in using NCEM and compared with values generated using RCEM.
islets isolated with low-dose RCEM compared with standard-dose NCEM. Overall, the data suggest that purified low-dose RCEM is more effective in recovering functional human islets than purified natural collagenase.
Our previous study using the same recombinant collagenase and supplemental dose of purified BP-Protease to isolate human islets from the body-tail of research pancreata demonstrated there was no statistically significant difference in the effectiveness of recombinant collagenase to recover human islets when 4 different purified collagenase-protease enzyme mixtures were used in the isolation procedures.
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The success of the 30:70 rC1:rC2 ratio in achieving similar islet yields in 7 additional islet isolations using intact human pancreas in the present study supports the validity of the prior results. These results appear contradictory to previous reports that suggested that excessive class II collagenase may be detrimental to isolation outcomes and 60:40 mass ratios of C1:C2 appeared optimum for human islet isolation. However, these conclusions were drawn from isolations performed with thermolysin, not BP-Protease. Moreover, the collagen degradation activity of the natural collagenases used in these earlier studies was not characterized using an appropriate substrate, further confounding interpretation of these results. This, combined with the fact that recombinant collagenases have in vitro collagen degradation characteristics that differ from the natural collagenases, makes comparisons between studies complicated. 4, 8, 9 In the present study, islet isolation results were generated from enzyme mixtures that used the same dose of BP-Protease as used F I G U R E 1 Islets isolated using low-dose (RCEM) result in less surface damage. Scanning electron microscopy (SEM) images indicate that islets isolated using (A) low-dose RCEM have an intact islet surface compared with islets isolated using (B) standard-dose (NCEM), resulting in a disrupted islet surface. The images in figure 1A and 1B are representative of several SEM images taken NCEM. An earlier report compared the effectiveness of natural and recombinant purified enzymes to isolate human islets. 29 There were no significant differences between any of the islet isolation parameters when results from islet isolations using these 2 enzyme mixtures were compared. islet yield, quality, and function. It has been reported that the commonly used dose of collagenase usually ranges from 21 to 32 WU/g of pancreatic tissue for human islet isolation. 4, 30 However, a recent study has reported that only 30% of the total FALGPA activity (measure of C2 activity) is absorbed by the pancreas during the perfusion process, 17 suggesting that a vast amount of enzyme is not used during standard islet isolation protocols.
In this context, low-dose RCEM appears to be notable advance to improve the yield and function of human islets recovered after digestion with collagenase-protease enzyme mixtures. The results summarized here strongly suggest the recombinant collagenases possess an intrinsic superiority to the naturally derived collagenases, but the biochemistry responsible for this has yet to be identified. This improvement is aligned with the evolving regulatory challenges that will likely demand the use of animal origin-free materials in the islet isolation process and economic considerations regarding the cost effectiveness of islet transplantation that justifies reimbursement by third party payers.
